VANCOUVER, March 24 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. (the Company) , a biotechnology company developing drugs in the field of chemokines, today announced that investigators at the National Cancer Institute (NCI) have demonstrated the potential pathways whereby the Company's anti-cancer compound CTCE-9908 reduces metastatic nodules in a model of osteosarcoma (a type of bone cancer). CTCE-9908 is designed to inhibit the growth and spread of certain common cancers with the potential for use with existing therapies (chemotherapy, surgery, and radiation) to improve treatment outcomes.
Osteosarcoma is a form of bone cancer that occurs in children and young adults and spreads (metastasizes) primarily to the lungs. NCI scientists have previously shown that CTCE-9908 reduces cancer metastasis by 67%. The present study examined the potential mechanisms that lead to the inhibition of cancer metastasis. The NCI will present their findings to the public on April 2nd at the American Association for Cancer Research (AACR) 2006 Annual Meeting, to be held in Washington, DC. The abstract will be available on the AACR website at www.AACR.org. Detailed findings from the study will be presented at the conference.
About CTCE-9908
Chemokine expects to expand its CTCE-9908 clinical program with the filing of an IND to the FDA. In preclinical studies, CTCE-9908 has been shown to reduce cancer metastases by 50-70% and to have anti-angiogenic properties. CTCE-9908 is designed to block the receptors that the chemokine SDF-1 binds to. SDF-1 (Stromal Cell Derived Factor 1) is believed to activate two sets of receptors, CXCR4 and CXCR7, which have been implicated in cancer growth and metastasis. These receptors are present on most human tumors cells, including lung, breast, prostate, colon, ovarian, bone, brain, and skin cancer. Leading cancer researchers have demonstrated that a high level of CXCR4 and CXCR7 expression in cancer cells is correlated to tumor progression, high metastasis rate and low patient survival rate.
About Chemokine Therapeutics Corp.
Chemokine Therapeutics is a product-focused biotechnology company developing drugs that harness the therapeutic potential of stem cells through chemokine pathways. Chemokines are a class of proteins that signal biological responses from stem cells, which play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, as well as tissue repair and regeneration. Stem cells are the master primitive cells that give rise to all of the cells and organs in the body. Chemokines are one of the major mediators of stem cell activity including stem cell growth, differentiation and maturation. Chemokine Therapeutics is a leader in research in this field. The Company has five products with two lead product candidates in clinical trials; CTCE-0214, for enhancing the immune system, and CTCE-9908, to prevent the spread of cancer and its continued growth. For more information, please visit its website at www.chemokine.net.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding managements' future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward- looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
For further information contact: -------------------------------- Corporate Contact: Frederica Bell Director, Investor Relations Chemokine Therapeutics Corp. (604) 827-3131 fbell@chemokine.net --------------------------------
Chemokine Therapeutics Corp.CONTACT: Corporate: Frederica Bell, Director, Investor Relations,Chemokine Therapeutics Corp., (604) 827-3131, fbell@chemokine.net
